HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Lung Adenocarcinoma

Lung adenocarcinoma is a type of non-small cell lung cancer that originates in the glandular cells of the lungs. It is the most common subtype of lung cancer and often affects both smokers and non-smokers. Adenocarcinoma typically develops in the outer regions of the lungs and can spread to other parts of the body. This cancer is known for its diverse range of genetic mutations, which can influence its behavior and response to treatment. The symptoms of lung adenocarcinoma may include persistent cough, shortness of breath, chest pain, and unintentional weight loss. Due to its tendency to spread early, it is often diagnosed at advanced stages. Diagnosis involves imaging studies, such as CT scans and biopsies, to confirm the presence of adenocarcinoma cells. Treatment options depend on the stage of the cancer and may include surgery, chemotherapy, targeted therapy, and immunotherapy. The prognosis varies, with early detection offering a better chance of successful treatment. Preventive measures focus on avoiding tobacco smoke and environmental pollutants. Additionally, early detection through regular screenings is crucial for improving outcomes. Lung adenocarcinoma remains a significant global health concern, and ongoing research aims to enhance our understanding of its biology and identify more effective treatment strategies.

Committee Members
Speaker at International Cancer Conference 2026 - Rajvir Dahiya

Rajvir Dahiya

University of California San Francisco, United States
Speaker at International Cancer Conference 2026 - Patricia Tai

Patricia Tai

UpToDate, Canada
Speaker at International Cancer Conference 2026 - Jose Manuel Cervera Grau

Jose Manuel Cervera Grau

Preclinical Lab and Computational Drug Discovery Program, Relayer Biotech Inc, Spain

Submit your abstract Today

Facebook Twitter XTwitter Youtube
Watsapp